PTC Therapeutics/Genzyme's ataluren fails in Phase IIb muscular dystrophy trial
11 March 2010
Asher Mullard
Please Login to read the full article.
11 March 2010
Asher Mullard
asher.mullard@informa.com
PTC Therapeutics and Genzyme's ataluren, an experimental nonsense mutation suppressor, has failed in nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD), show top-line Phase IIb results. Around 10-15% of DBMD cases are due to nonsense mutations.
Despite the failure, Dr Langdon...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Roche pays $30 million up front for preclinical rare disease programme
- PhRMA reports record number of rare disease drug candidates under development
- Prosensa/GSK hopes for Phase III DMD recruitment boost from published data
- Celgene Pays Acceleron $25M up front under anaemia drug partnership
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
